Adage Capital Partners’s Amicus Therapeutics FOLD Stock Holding History

Adage Capital Partners’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,650,000	Closed	-$23.9M	–	1034
2026 Q1	$23.9M	Hold	1,650,000	–	–	0.04%	425
2025 Q4	$23.5M	Buy	+1,650,000	New	+$16.2M	0.04%	430
2022 Q3	–	Sell	-848,157	Closed	-$9.11M	–	1069
2022 Q2	$9.11M	Buy	848,157 +298,157	+54%	+$2.46M	0.02%	692
2022 Q1	$5.21M	Buy	+550,000	New	+$5.16M	0.01%	827
2018 Q2	–	Sell	-1,450,000	Closed	-$21.8M	–	755
2018 Q1	$21.8M	Buy	+1,450,000	New	+$22.1M	0.05%	378

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Adage Capital Partners's FOLD Position: Q2 2026 in Review

Adage Capital Partners sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 1,650,000 shares — an estimated $23.9M sold.

Adage Capital Partners first reported a position in FOLD in Q1 2018 and held it in 5 quarters. The position peaked at $23.9M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Adage Capital Partners reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Adage Capital Partners sold 1,650,000 Amicus Therapeutics shares in Q2 2026, an estimated $23.9M.
Adage Capital Partners first reported a position in Amicus Therapeutics in Q1 2018 and held it in 5 quarters.
Adage Capital Partners's Amicus Therapeutics position peaked at $23.9M in Q1 2026.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.